Malign Katatoni

Abstract

Katatoni mutizm, hareketsizlik, negativizm, stereotipi, mannerizm, ekofenomen, perseverasyon ve pasif itaat ile karakterize bir sendromdur. Altta yatan nedenler psikiyatrik olabildiği gibi nörolojik ve genel tıbbi durum ile ilişkili olabilir. Bunun yanı sıra katatoni malign ve malign olmayan olarak iki alt tipe ayrılır. Malign katatonide tabloya hipertermi, otonomik bulgular da eşlik eder. Otonomik bulgular arasında taşikardi, takipne, hiperhidrozis başta gelir. Hastalığın tanısının erken konması uygun tedavinin verilmesi açısından önemlidir. Klinisyenler bu hastalığın ölümcül seyredebileceğini bilmelidirler.

Keywords

• Katatoni, Malign Katatoni, Nöroleptik Malign Sendrom

Malignant Catatonia

Abstract

Catatonia is a syndrome characterized by mutism, immobility, negativism, stereotypy, mannerisms, echophenomena, perseveration and passive obedience. The underlying causes can be psychiatric or may be associated with general medical status or neurological diseases. Additionally catatoni has two subtypes as malignant and nonmalignant catotonia. Main symptoms of malignant catatonia are hyperthermia and autonomic symptoms such as tachycardia, tachypnea and hyperhidrosis. It is important to make the diagnosis as early as possible for an appropriate medical treatment. Clinicians should be aware of the fatal outcome of the disease.

Keywords

• Catatonia, Malign Catatonia, Neuroleptic Malign Syndrome

References

1. Kahlbaum KL. Catatonia. Baltimore, Johns Hopkins University Press, 1973.
2. Fink M, Taylor MA. Catatonia: A Clinician’s Guide to Diagnosis and Treatment. Cambridge, UK, Cambridge University Press, 2003.
3. Taylor M, Fink M. Catatonia in psychiatric classification: a home of its own. Am J Psychiatry 2003; 160:1233-1241.
4. Taylor M, Abrams R. Catatonia: prevalence and importance in the manic phase of manic depressive illness. Arch Gen Psychiatry 1977; 34:1223-1225.
5. Hung Y, Huang T. Lorazepam and diazepam rapidly relieve catatonic features in major depression. Clin Neuropharmacol 2006; 29:144-147.
6. Ungvari GA, Rankin JF. Lorazepam monotherapy for catatonic stupor. J Clin Psychopharmacology 1989; 9:154.
7. Bush G, Fink M, Petrides G, Dowling F, Francis A. Catatonia II. Treatment with lorazepam and electroconvulsive therapy. Acta Psychiatr Scand 1996; 93:137-143.
8. Elia J, Dell M, Friedman D, Zimmerman R, Balamuth N, Ahmed A et al. PANDAS with catatonia: a case report. Therapeutic response to lorazepam and plasmapheresis. J Am Acad Child Adolesc Psychiatry 2005; 44:1145-1150.

9. Fink M, Taylor MA. Catatonia: subtype or syndrome in DSM? Am J Psychiatry 2006; 163:1875-1876.
10. Rosebush PI, Mazurek MF. A consideration of the mechanisms by which lorazepam might treat catatonia. J Clin Psychiatry 1991; 52:187-188.
11. Salam SA, Pillai AK, Beresford TP. Lorazepam for psychogenic catatonia. Am J Psychiatry 1987; 144:1082-1083.
12. Cook EH, Olson K, Pliskin N. Response of organic catatonia to risperidone. Arch Gen Psychiatry 1996; 53:82-83.
13. Fricchione GL, Cassem NH, Hooberman D. Intravenous lorazepam in neuroleptic- induced catatonia J Clin Psychopharmacol 1983; 3:338-342.
14. Abrams R, Taylor MA. Catatonia. A prospective clinical study. Arch Gen Psychiatry 1976; 33:579-581.
15. Abrams R, Taylor MA, Storulow KAC. Catatonia and mania: Patterns of cerebral dysfunction. Biol Psychiatry 1979; 14:111-117.
16. Detweiler MB, Mehra A, Rowell T, Kim KY, Bader G. Delirious mania and malignant catatonia: A report of 3 cases and review. Psychiatr Q 2009; 80:23-40.
17. Morrison JR. Catatonia: Retarded and excited types. Arch Gen Psychiatry 1973; 28:39- 41.
18. Morrison JR. Karl Kauhlbaum and catatonia. Compr Psychiatry 1974;15:315-316.
19. Morrison JR. Catatonia: Diagnosis and treatment. Hosp Community Psychiatry 1975; 26:91-94.
20. Gelenburg AJ. The catatonic syndrome. Lancet 1976;1 (7973): 339-341.
21. Primavera A, Fonti A, Novello P, Roccatagliata G, Cocito L. Epileptic seizures in patients with acute catatonic syndrome. J Neurol Neurosurg Psychiatry 1994; 54:1419-1422.
22. Thakur A, Jagadheesan K, Dutta S, Sinha VK. Incidence of catatonia in children and adolescents in a paediatric psychiatric clinic. Aust NZJ Psychiatry 2003; 37:200-203.
23. Heikkilä J, Raitasuo S, Lauerma H, Mölsä P. Catatonia and neuroleptic malignant syndrome in a mentally retarded patient. Duodecim 1992; 108:1120-1124.
24. Gaind GS, Rosebush PI, Mazurek MF Lorazepam treatment of acute and chronic catatonia in two mentally retarded brothers. J Clin Psychiatry 1994; 55:20-23.
25. Dent J. Catatonic syndrome following recovery from neuroleptic malignant syndrome J Intellect Disabil Res 1995; 39:457-459.
26. Fink M. Neuroleptic malignant syndrome: One entity or two? Biol Psychiatry 1996; 39:1-4.
27. Fricchione G, Mann SC, Caroff SN. Catatonia, lethal catatonia and neuroleptic malignant syndrome. Psychiatr Ann 2000; 30:347-355.
28. Frucht SJ, Fahn S. Movement Disorder Emergencies: Diagnosis and Treatment 1st Ed. Totowa, New Jersey, Humana, 2005.
29. Caroff SN, Mann S, Francis A, Fricchione G. Catatonia from Psychopathology to Neurobiology 1st Ed., Arlington, American Psychiatric Publishing, 2004.
30. Carroll BT, Taylor BE. The nondichotomy between lethal catatonia and neuroleptic malignant syndrome. J Clin Psychopharmacol 1997; 17:235-236.
31. Carroll BT, Graham KT, Thalassinos AJ. A common pathogenesis of the serotonin syndrome, catatonia, and neuroleptic malignant syndrome. J Neuropsychiatry Clin Neurosci 2001; 13:150.
32. Northoff G. Neuroleptic malignant syndrome: One entity or two? Biol Psychiatry 1996; 40:431-433.
33. Philbrick KL, Rummans TA. Malignant catatonia. J Neuropsychiatry Clin Neurosci 1994; 6:1-13.
34. Francis A. Catatonia: diagnosis, classification, and treatment. Curr Psychiatry Rep 2010; 12:180-185.
35. Castillo E, Rubin RT, Holsboer-Trachsler E. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. Am J Psychiatry 1989; 146: 324-328.
36. Mann SC, Caroff SN, Bleier HR, Welz WK, Kling MA, Hayashida M. Lethal catatonia. Am J Psychiatry 1986; 143:1374-1381.
37. Peralta V, Cuesta MJ, Serrano JF, Mata I. The Kahlbaum syndrome: a study of its clinical validity, nosological status, and relationship with schizophrenia and mood disorder. Compr Psychiatry 1997; 38:61-67,.
38. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision. Washington, DC, American Psychiatric Association, 2000.
39. Adityanjee, Singh S, Singh G, Ong S. Spectrum concept of neuroleptic malignant syndrome. Br J Psychiatry 1988; 153:107-111.
40. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142:1137-1145.
41. Pope HG, Jr, Keck PE, Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 1986; 143:1227- 1233.
42. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993; 77:185-202.
43. Addonizio G, Susman VL, Roth SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry 1986; 143:1587-1590.
44. Weder ND, Muralee S, Penland H, Tampi RR. Catatonia: A Review. Ann Clin Psychiatry 2008; 20:97-107.
45. Kontaxakis VP, Havaki-Kontaxaki BJ, Christodoulou NG, Paplos KG, Christodoulou GN. Olanzapine-associated neuroleptic malignant syndrome: Is there an overlap with the serotonin syndrome? Ann Gen Hosp Psychiatry 2003; 2:10.
46. Guzofski S, Peralta R. Neuroleptic malignant syndrome with attention to its occurrence with atypical antipsychotic medication: A review. Jefferson Journal of Psychiatry 2006; 20:53-61.
47. Fink M, Taylor MA. The many varieties of catatonia. Eur Arch Psychiatry Clin Neurosci 2001; 251(Suppl 1):I8-I13.
48. Levin T, Martin R. Classification of catatonia. Am J Psychiatry 2004; 161:1136.
49. Swartz C, Francis A, Malur C. Delirium or catatonic disorder due to a general medical condition. J ECT 2002; 18:167-168.
50. Taylor MA. Catatonia: A review of behavioral neurologic syndrome. Neuropsychiatry Neuropsychol Behav Neurol 1990; 3:48-72.
51. Fink M, Taylor MA. The catatonia syndrome: forgotten but not gone. Arch Gen Psychiatry 2009; 66:1173-1177.
52. Taylor MA, Fink M. Catatonia as a psychiatric classification: Home of its own. Am J Psychiatry 2003; 160:1233-1241.
53. Rosebush PI, Hildebrand AM, Furlong BG, Mazurek MF. Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry 1990; 51:357-362.
54. Ungvari GS, Leung HC, Lee TS. Benzodiazepines and the psychopathology of catatonia. Pharmacopsychiatry 1994; 27:242-245.
55. Schmider J, Standhart H, Deuschle M, Drancoli J, Heuser I. A double-blind comparison of lorazepam and oxazepam in psychomotor retardation and mutism. Biol Psychiatry 1999; 46:437-441.
56. Petrides G, Divadeenam KM, Bush G, Francis A. Synergism of lorazepam and electroconvulsive therapy in the treatment of catatonia. Biol Psychiatry 1997; 42:375-381.
57. Margetic B, Margetic BA. Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiol Drug Saf, 2010; 19:429-435.
58. Kaufman KR, Levitt MJ, Schiltz JF, Sunderram J. Neuroleptic malignant syndrome and serotonin syndrome in the critical care setting: case analysis. Ann Clin Psychiatry 2006; 18: 201–204.
59. Odagaki Y. Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics? Curr Drug Saf 2009; 4: 84-93.
60. Thomas C, Carroll BT, Maley RT, Jayanti K, Koduri A. Memantine and catatonic schizophrenia. Am J Psychiatry 2005; 162:626.
61. Carpenter SS, Hatchett AD, Fuller MA. Catatonic schizophrenia and the use of memantine. Ann Pharmacother 2006; 40:344-346.
62. Kritzinger PR, Jordaan GP. Catatonia: an open prospective series with carbamazepine. Int J Neuropsychopharmacol 2001; 4:251-257.
63. McDaniel WW SD, Sahota AK. Topiramate efect in catatonia: a case series. J Neuropsychiatry Clin Neurosci 2006; 18:234-238.
64. Cottencin O, Warembourg F, de Chouly de Lenclave MB, Lucas B, Vaiva G, Goudemand M et al. Catatonia and consultation- liaison psychiatry study of 12 cases. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1170-1176
65. Grisaru N, Chudakov B, Yaroslavsky Y, Belmaker RH. Catatonia treated with transcranial magnetic stimulation. Am J Psychiatry 1998; 155:1630.
66. Saba G, Rocamora JF, Kalalou K, Benadhira R, Plaze M, Aubriot-Delmas B et al. Catatonia and transcranial magnetic stimulation. Am J Psychiatry. 2002; 159:1794.